Details for Patent: 7,842,699

Title:	Pyrrolo[2,3-D]pyrimidine compounds
Abstract:	A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Inventor(s):	Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT)
Assignee:	Pfizer Inc. (Madison, NJ)
Filing Date:	Aug 28, 2009
Application Number:	12/549,526
Claims:	1. A method for treating atopic dermatitis comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal in need thereof. 2. The method of claim 1 comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal in need thereof. 3. The method of claim 2 wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts. 4. The method of claim 1 wherein the therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or pharmaceutically acceptable salt thereof is administered orally. 5. The method of claim 1 wherein the mammal is a human. 6. The method of claim 1 further comprising administering the therapeutically effective amount of one or more additional agents which modulate a mammalian immune system or antiinflammatory agents to the mammal in need thereof. 7. A method for treating ulcerative colitis comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal in need thereof. 8. The method of claim 7 comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal in need thereof. 9. The method of claim 8 wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts. 10. The method of claim 7 wherein the therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or pharmaceutically acceptable salt thereof is administered orally. 11. The method of claim 7 comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal in need thereof. 12. The method of claim 7 further comprising administering the therapeutically effective amount of one or more additional agents which modulate a mammalian immune system or antiinflammatory agents to the mammal in need thereof. 13. A method for treating Crohn's disease comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile or a pharmaceutically acceptable salt thereof to a mammal in need thereof. 14. The method of claim 13 comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal in need thereof. 15. The method of claim 14 wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts. 16. The method of claim 13 wherein the therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperid- in-1-yl}-3-oxo-propionitrile or pharmaceutically acceptable salt thereof is administered orally. 17. The method of claim 13 comprising administering a therapeutically effective amount of 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-- 1-yl}-3-oxo-propionitrile to the mammal in need thereof. 18. The method of claim 13 further comprising administering the therapeutically effective amount of one or more additional agents which modulate a mammalian immune system or antiinflammatory agents to the mammal in need thereof.